• CapsuleTech (Boston) reported that Trinity Health, the fourth-largest Catholic healthcare system in the U.S., will implement Capsule’s DataCaptor connectivity suite at two of its hospitals. Trinity Health will be using the DataCaptor to automate the capture of patient data from bedside devices, including GE Monitors from the unity network. DataCaptor collects the data, converts it into HL7 format and integrates it into the hospitals’ Cerner Millenium Clinical Information System (CIS). As one of the largest Cerner clients, with 43 hospitals in its network, Trinity Health will be implementing DataCaptor at Battle Creek Health System (Battle Creek, Michigan) for Cerner’s SurgiNet OR solution and at Holy Cross Hospital (Silver Spring, Maryland) for Cerner’s INet ICU solution. CapsuleTech makes connectivity solutions for healthcare institutions.

• diaDexus (South San Francisco, California) reported FDA clearance for a new automated version of its PLAC Test. The new PLAC format, based on immuno-turbidimetric technology, is an automated immunoassay designed to run on common existing laboratory equipment, including clinical chemistry analyzers from Hitachi, Roche/Hitachi, and Olympus. The PLAC test is a blood test that measures lipoprotein-associated phospholipase A₂ (Lp-PLA₂), an enzyme specific to vascular inflammation implicated in the formation of rupture-prone plaque. The PLAC Test is the only blood test cleared by the FDA to aid in assessing risk of both coronary heart disease and ischemic stroke associated with atherosclerosis. diaDexus is a privately held company focused on the development and commercialization of novel, patent-protected diagnostic products with high clinical value.

• Innocoll (Ashburn, Virginia) said that the second of two Phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies, to investigate CollaRx Gentamicin Surgical Implant for the prevention of surgical site infections, has commenced dosing. The implant is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll’s collagen-based drug delivery technology, CollaRx, and is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. Innocoll is a privately-held specialty pharmaceutical company.

• Global Med Technologies (Denver) reported FDA clearance for ElDorado Donor — a new blood management product produced by its Wyndgate Technologies division. The ElDorado Donor is intended as a comprehensive blood management software application created to provide for the information system needs of blood bank and donor centers. The software is designed to manage, automate, and control activities associated with donors, donor collections, testing, manufacturing, inventory, and distribution. ElDorado Donor was developed with scalability in mind and is designed to manage the system needs of diverse facilities, from small hospital blood banks to community blood centers, to regional and national centers. Using an integrated modular configuration, ElDorado Donor is intended to offer functionality with flexibility to tailor features within the system to a facility’s specific needs supporting process control from collection to distribution. Global Med Technologies is an e-health medical information technology company.